Patents by Inventor Philipp Oster

Philipp Oster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8808711
    Abstract: OMVs targeted against specific epidemic strains can be highly effective in controlling localized outbreaks of disease. In combination with large-scale and reproducible manufacturing techniques, a vaccine can be rapidly produced after an outbreak. The invention provides a method for preparing a meningococcal outer membrane vesicle (OMV) vaccine, comprising the steps of: (i) identifying the serosubtype of a meningococcal strain associated with an outbreak of meningococcal meningitis; (ii) preparing OMVs from a meningococcal strain having the serosubtype identified in step (i) for use in vaccine manufacture. The method may comprise one or both of the further steps of (iii) formulating said OMVs as a vaccine; and (iv) distributing said vaccine in a geographical area affected by or likely to be affected by said outbreak. The meningococcal strain will typically be in serogroup B, but may be instead by in serogroup A, C, W135, Y, etc.
    Type: Grant
    Filed: September 5, 2005
    Date of Patent: August 19, 2014
    Assignee: Novartis AG
    Inventors: Philipp Oster, Mariagrazia Pizza, Rino Rappouli
  • Publication number: 20080063665
    Abstract: OMVs targeted against specific epidemic strains can be highly effective in controlling localised outbreaks of disease. In combination with large-scale and reproducible manufacturing techniques, a vaccine can be rapidly produced after an outbreak. The invention provides a method for preparing a meningococcal outer membrane vesicle (OMV) vaccine, comprising the steps of: (i) identifying the serosubtype of a meningococcal strain associated with an outbreak of meningococcal meningitis; (ii) preparing OMVs from a meningococcal strain having the serosubtype identified in step (i) for use in vaccine manufacture. The method may comprise one or both of the further steps of (iii) formulating said OMVs as a vaccine; and (iv) distributing said vaccine in a geographical area affected by or likely to be affected by said outbreak. The meningococcal strain will typically be in serogroup B, but may be instead by in serogroup A, C, W135, Y, etc.
    Type: Application
    Filed: September 5, 2005
    Publication date: March 13, 2008
    Inventors: Philipp Oster, Mariagrazia Pizza, Rino Rappouli
  • Patent number: D866751
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: November 12, 2019
    Assignee: Sanofi
    Inventors: Christian Rogge, Philipp Oster, Carolin Frontzek, James Collins, Alex Zuyev, Kai Scheinert, Uwe Dasbach
  • Patent number: D866752
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: November 12, 2019
    Assignee: Sanofi
    Inventors: Christian Rogge, Philipp Oster, Carolin Frontzek, James Collins, Alex Zuyev, Kai Scheinert, Uwe Dasbach
  • Patent number: D867588
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: November 19, 2019
    Assignee: Sanofi
    Inventors: Christian Rogge, Philipp Oster, Carolin Frontzek, James Collins, Alex Zuyev, Kai Scheinert, Uwe Dasbach
  • Patent number: D908868
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: January 26, 2021
    Assignee: Sanofi
    Inventors: Christian Rogge, Philipp Oster, Carolin Frontzek, James Collins, Alex Zuyev, Kai Scheinert, Uwe Dasbach, Marc Schader
  • Patent number: D926967
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: August 3, 2021
    Assignee: Sanofi
    Inventors: Christian Rogge, Philipp Oster, Carolin Frontzek, James Collins, Alex Zuyev, Kai Scheinert, Uwe Dasbach, Marc Schader
  • Patent number: D988507
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: June 6, 2023
    Assignee: Sanofi
    Inventors: Christian Rogge, Philipp Oster, Carolin Frontzek, Uwe Dasbach, Alex Zuyev, William Timmis